DGIdb - VINCRISTINE Drug Record

VINCRISTINE chembl:CHEMBL90555 ApprovedAntineoplasticImmunotherapy

Alternate Names:

VINCRISTINE
LEUROCRISTINE
NSC-67574
LEUROCRISTINE SULFATE
VINCRISTIN
ONCOVIN®
22-OXOVINCALEUKOBLASTINE
VINCRISTINUM
KYOCRISTINE
22-OXOVINCALEUKOBLASTIN
VINCRISTINA
pubchem.compound:5978
chemidplus:57-22-7
rxcui:11202
chembl:CHEMBL90555
drugbank:00541

Drug Info:

Drug Categories	tubulin modulators
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	1963
Drug Class	antineoplastic agents
Drug Categories	agents causing muscle toxicity
Drug Categories	bsep/abcb11 substrates
Drug Categories	bsep/abcb11 substrates with narrow therapeutic index
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	narrow therapeutic index drugs
Drug Categories	neurotoxic agents
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	oatp1b3 inhibitors
Drug Categories	p-glycoprotein inducers
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index

(8 More Sources)

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.
Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem
Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem
Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation
Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
Kurtzberg et al., 2009, Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents., Cancer Chemother. Pharmacol.
Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
Yasui et al., 2010, Live cell imaging of micronucleus formation and development., Mutat. Res.
Vilpo et al., 2000, Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro., Eur. J. Haematol.
Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology
Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer
Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.
Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.
Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
Lopez-Lopez E et al., 2016, Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia., Pharmacogenomics
Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.
Andreani A et al., 2008, Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events., J Med Chem
Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
Klauber et al., 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol., Cancer Res.
McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
Fujiwara et al., 2007, Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated., Mol. Cancer Ther.
Shingu et al., 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells., Cancer Res.
Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta
Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood

VINCRISTINE TUBB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

Publications:

Kurtzberg et al., 2009, Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents., Cancer Chemother. Pharmacol.

Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

VINCRISTINE TUBA4A

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

Publications:

Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.

Yasui et al., 2010, Live cell imaging of micronucleus formation and development., Mutat. Res.

Vilpo et al., 2000, Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro., Eur. J. Haematol.

VINCRISTINE ABL1

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

Publications:
VINCRISTINE BCR

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

Publications:

VINCRISTINE GSTA1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia

VINCRISTINE BDNF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.

VINCRISTINE TUBB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE PNPLA3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther

VINCRISTINE TUBA3C

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE DROSHA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
VINCRISTINE NRG1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation
VINCRISTINE CXCL12

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

VINCRISTINE TUBB4B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE TUBB2B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE DOK5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
VINCRISTINE LINC00251

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

VINCRISTINE TUBB8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE GATA3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
VINCRISTINE ATRX

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
VINCRISTINE NTF3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology

VINCRISTINE AFP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer

VINCRISTINE VWF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.
VINCRISTINE ABCB4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.
VINCRISTINE CP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.
VINCRISTINE ABCC3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One

VINCRISTINE ABCB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica

Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J

VINCRISTINE TUBA3E

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE TUBB2A

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE RALBP1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lopez-Lopez E et al., 2016, Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia., Pharmacogenomics
VINCRISTINE CDKN1B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.

VINCRISTINE ODC1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Andreani A et al., 2008, Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events., J Med Chem

VINCRISTINE TUBA1C

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE MYCN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
VINCRISTINE FGF2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Klauber et al., 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol., Cancer Res.

VINCRISTINE TUBA3D

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE TOP2A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.

VINCRISTINE TUBA1B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE PIK3CG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Fujiwara et al., 2007, Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated., Mol. Cancer Ther.

Shingu et al., 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells., Cancer Res.

VINCRISTINE PIK3CA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Shingu et al., 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells., Cancer Res.

VINCRISTINE TUBB3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE TYMS

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta

VINCRISTINE TUBA1A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE SRI

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
VINCRISTINE BMP7

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

VINCRISTINE TUBB4A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

VINCRISTINE TUBB6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

VINCRISTINE CEP72

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
VINCRISTINE CAPG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE BCL2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE ACTG1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE ABCC10

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE NR1I2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE CYP3A5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE ABCC2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE SMAD3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE ABCC1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE GMNN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VINCRISTINE AR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00541

Version: 5.1.7

Alternate Names:

VINCRISTINE DrugBank Drug Name

57-22-7 CAS Number

Alcavixin Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Yasui et al., 2010, Live cell imaging of micronucleus formation and development., Mutat. Res.

Vilpo et al., 2000, Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro., Eur. J. Haematol.

Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.

TEND: VINCRISTINE
- Version: 01-August-2011
Alternate Names:

VINCRISTINE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1963

Publications:
TdgClinicalTrial: VINCRISTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: VINCRISTINE

Version: 02-September-2020

Alternate Names:

CHEMBL90555 ChEMBL Drug ID

Drug Info:

Publications:

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

NCI: VINCRISTINE

Version: 14-September-2017

Alternate Names:

C933 NCI drug code

Drug Info:

Publications:

Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta

Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.

Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.

PharmGKB: vincristine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

CIViC: VINCRISTINE
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
TTD: Vincristine
- Version: 2020.06.01
Alternate Names:

D09QVV TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103391
- Version: 29-September-2020
Alternate Names:

VINCRISTINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL90555
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Vincristine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: VINCRISTINE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Trial Name	vincristine sulfate liposomes injection, Onco TCS,Marqibo
Novel drug target	Established target

VINCRISTINE	DrugBank Drug Name
57-22-7	CAS Number
Alcavixin	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

VINCRISTINE Drug Record

VINCRISTINE chembl:CHEMBL90555 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo Novel drug target Established target

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo Novel drug target Established target

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One

Interaction Types & Directionality:

n/a

Publications:

Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation

Interaction Types & Directionality:

n/a

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Interaction Types & Directionality:

n/a

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet

Interaction Types & Directionality:

n/a

Publications:

Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.

Interaction Types & Directionality:

n/a

Publications:

Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology

Interaction Types & Directionality:

n/a

Publications:

Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer

Interaction Types & Directionality:

n/a

Publications:

Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.

Interaction Types & Directionality:

n/a

Publications:

Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.

Interaction Types & Directionality:

n/a

Publications:

Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.

Interaction Types & Directionality:

n/a

Publications:

Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

Interaction Types & Directionality:

n/a

Publications:

Lopez-Lopez E et al., 2016, Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia., Pharmacogenomics

Interaction Types & Directionality:

n/a

Publications:

Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.

Interaction Types & Directionality:

n/a

Publications:

Andreani A et al., 2008, Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events., J Med Chem

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.

Interaction Types & Directionality:

n/a

Publications:

Klauber et al., 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol., Cancer Res.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.